A clinical trial to study the antimicrobial efficiency of magnesium oxide nanoparticles ( MgONPâ??s) based intracanal medicament In patients with apical periodontitis - A Randomized Clinical Trial

ANTIMICROBIAL EFFICIENCY OF MAGNESIUM OXIDE NANOPARTICLES BASED INTRACANAL MEDICAMENT IN PATIENTS WITH APICAL PERIODONTITIS- A RANDOMIZED CLINICAL TRIAL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/01/039846

Enrollment

Registered

2022-01-31

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K044- Acute apical periodontitis of pulpal origin

Interventions

Intervention1: Magnesium oxide Nanoparticles as an Intracanal medicament ( 15.25ul - 250ul): Magnesium oxide nanoparticles is a light metal based Antimicrobial nanoparticle that can be metabolised and

Eligibility

Inclusion criteria

Inclusion criteria: Patients with Non vital teeth with PAI scoring 1-3, 18 - 55 years of age,

Exclusion criteria

Exclusion criteria: Medically compromised individuals individuals with vital pulp Individuals with peripaical lesion( PAI Score- 4-5) Endo perio lesion

Design outcomes

Primary

Measure	Time frame
Reduction of Microbial load will be assessed by RT-PCR methodTimepoint: 1 week Microbial load ( Reduction of microbial load)	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactKALYANI BEHERA

SAVEETHA DENTAL COLLEGE AND HOSPITAL

nasimiffat@gmail.com9940063567

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026